Inaugural CCF Stakeholder’s Meeting,  February 27-28, 2014

  • In collaboration with Huntsman Cancer Institute, the University of Utah, the Bili Project, and Target Cancer
  • 56 physicians and researchers attended from 27 US and international cancer centers
  • 9 working groups were formed to work cross-institutionally on basic, translational and clinical outcomes
  • Sessions focused on the latest updates, research, current data and treatment options for cholangiocarcinoma

 

Thanks to all the investigators for their contributions and commitment. Without everybody’s genuine efforts, it would not have been possible to come up with that many potentially fundable projects in that little period of time

—Ghassan K. Abou-Alfa, MD

Memorial Sloan-Kettering Cancer Center,

2014 Inaugural CCF Stakeholders Meeting Chair


First deliverable from 2014 Stakeholder’s Meeting!

Biliary Emergency Information Card

In an effort to educate patients and physicians about potentially fatal risks of ascending cholangitis, CCF has created the Biliary Emergency Information Card. Patients can quickly and easily complete a free, online form that populates the Biliary Emergency Information Card with patient information for their specific cholangiocarcinoma treatment and their health care providers’ contact information. The patients can print and fold the card so it is accessible at all times. Instructions on the card also include specific emergency treatment guidelines. Medical personnel can scan a QR code or visit the Foundation website for additional instructions on symptoms, signs, labs, workup, treatment and follow-up for the patient.

Learn more

Read Press Release


Genetic Models of Intrahepatic Cholangiocarcinoma

mac-nbardeesyNabeel Bardeesy, PhD

Dana-Farber/Harvard Cancer Center

Summary

All cancers have genetic mutations that cause cells to grow abnormally. Patients with cholangiocarcinoma have different combinations of such mutations that result in distinct subtypes of the disease and may have their own specific responses to therapy. It is therefore important to develop relevant model systems to understand how these different mutations affect the biology of cholangiocarcinoma and the response to treatment. The most common mutations in cholangiocinoma occur in two closely related genes called Isocitrate Dehydrogenase 1 and 2 (IDH1, IDH2). The Bardeesy lab presented recent findings regarding how IDH mutations cause cholangiocarcinoma. In particular, they found that mutant IDH prevents liver stem cells from responding to normal signals to stop growing and maturing into normal liver cells. They also developed genetically engineered mouse models that enable the testing of new treatments for IDH mutant cholangiocarcinoma.

This work will be published in the upcoming 1-2 months and the findings will subsequently be made available on this website.


Immune Response to Cholangiocarcinoma

1550-1Cristina R. Ferrone, MD
Massachusetts General Hospital Cancer Center


Molecular Profiling of Cholangiocarcinoma

mjavieMilind Javle, MD

Associate Professor

Department of GI Medical Oncology

MD Anderson


Liver Transplantation for Hilar Cholangiocarcinoma

Robin mac-rokim D. Kim, MD

Executive Medical Director, Transplant Service Line Director, Hepatobiliary Cancer Program

Huntsman Cancer Institute and the University of Utah


Locoregional Therapies for Cholangiocarcinoma

Dr_Armeen_MahvashArmeen Mahvash, MD

Interventional Radiology

MD Anderson


CEACAM6 as a Biomarker for Cholangiocarcinoma

Rocha,FlavioVirginia Mason Medical Center

Flavio G. Rocha, MD, FACS

Summary

CEACAM6 as a biomarker for cholangiocarcinoma

Virginia Mason Medical Center

Flavio G. Rocha, MD, FACS

My research focuses on the identification and validation of protein biomarkers for the diagnosis and prognosis of bile duct cancer. Previous studies have demonstrated that CEACAM6, a cell surface glycoprotein member of the carcinoembryonic antigen family, is overexpressed in several gastrointestinal cancers. In addition, proteomic studies have shown that CEACAM6 is present in the bile of patients with malignant biliary strictures.

Using a tissue microarray assembled from archived biliary cancer specimens, CEACAM6 was found in half of extrahepatic cholangiocarcinomas (ECC) and a minority of intrahepatic cholangiocarcinomas (ICC) by immunohistochemistry. However, patients with ICC that expressed CEACAM6 had a significantly worse disease-specific survival despite curative resection.

Bile was collected from patients undergoing resection of both benign and malignant biliary disease. Biliary CEACAM6 levels were measured by enzyme-linked immunosorbent assay (ELISA) and confirmed by Western blot. Patients with cholangiocarcinoma had significantly higher levels of CEACAM6 in their bile. Receiver operator curves demonstrated a high sensitivity and specificity of CEACAM6 level for the diagnosis of ECC.

Current studies include the evaluation of CEACAM6 expression in a prospective clinical trial of hepatic arterial chemotherapy for unresectable ICC to determine prognostic capability and measurement of CEACAM6 levels in the serum of cholangiocarcinoma patients for predictive purposes.


Update on the International Hepatobiliary Neoplasia Registry and the Proposed Genome Wide Associations Study of Cholangiocarcinoma

lrobertsLewis Roberts, MB, ChB, PhD

Mayo Clinic


Our Photo Album

click on any image.

Thanks a lot, for a superb event. It’s hard to believe your organization is still so young, and you have already achieved so much. I have been to other such events before, but the enthusiasm in that room was very palpable.

—Milind Javle, MD - MD Anderson

2014 Cholangiocarcinoma Foundation Stakeholders Meeting Working Group Summaries

Thanks very much for the outstanding stakeholder meeting you organized last week.  It was great to meet the scientists and advocates and I look forward to seeing results from this meeting over the ensuing months and years.

—Lewis Roberts, MD - Mayo Clinic

First of all, I’d like to thank you for the invitation to this stimulating meeting and I’d also like to congratulate you for the fantastic work done by the Foundation.  I very much look forward to working closely with you and the whole group going forward.  We have new directions and collaborations that came directly from the meeting.  So the meeting was particularly valuable to us, both from getting to know the community and in stimulating ideas.

—Nabeel Bardeesy, PhD - Dana-Farber/Harvard Cancer Center

The conference was extremely well organized, coordinated and planned. The conference members you put together from across basic research, translation and clinical capabilities creates a complete eco-system to impact this field. . . the event will enable many collaborative discussions to advance the goals of the Foundation.

— Taher Abbasi, Cellworks Group